Zhejiang Tianyu Pharmaceutical Co., Ltd.

SZSE:300702 Stock Report

Market Cap: CN¥6.0b

Zhejiang Tianyu Pharmaceutical Future Growth

Future criteria checks 4/6

Zhejiang Tianyu Pharmaceutical is forecast to grow earnings and revenue by 71.4% and 16.8% per annum respectively. EPS is expected to grow by 71.3% per annum. Return on equity is forecast to be 7.9% in 3 years.

Key information

71.4%

Earnings growth rate

71.3%

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth rate16.8%
Future return on equity7.9%
Analyst coverage

Low

Last updated13 Dec 2024

Recent future growth updates

Recent updates

Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Price Is Right But Growth Is Lacking

Dec 03
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Price Is Right But Growth Is Lacking

We Think Zhejiang Tianyu Pharmaceutical (SZSE:300702) Is Taking Some Risk With Its Debt

Nov 04
We Think Zhejiang Tianyu Pharmaceutical (SZSE:300702) Is Taking Some Risk With Its Debt

Concerns Surrounding Zhejiang Tianyu Pharmaceutical's (SZSE:300702) Performance

Sep 04
Concerns Surrounding Zhejiang Tianyu Pharmaceutical's (SZSE:300702) Performance

Take Care Before Diving Into The Deep End On Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702)

Aug 21
Take Care Before Diving Into The Deep End On Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702)

Further Upside For Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) Shares Could Introduce Price Risks After 27% Bounce

May 21
Further Upside For Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) Shares Could Introduce Price Risks After 27% Bounce

Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Revenues Are Not Doing Enough For Some Investors

Mar 17
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Revenues Are Not Doing Enough For Some Investors

Earnings and Revenue Growth Forecasts

SZSE:300702 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,7513402148773
12/31/20253,1532331333193
12/31/20242,6981032447473
9/30/20242,59544239425N/A
6/30/20242,44612129309N/A
3/31/20242,440-32-120118N/A
12/31/20232,52727-361-44N/A
9/30/20232,447-89-571-232N/A
6/30/20232,539-146-744-205N/A
3/31/20232,694-103-55740N/A
1/1/20232,667-119-576-49N/A
9/30/20222,69037-519-31N/A
6/30/20222,652119-542-29N/A
3/31/20222,536156-880-340N/A
1/1/20222,545205-999-262N/A
9/30/20212,523295-924-39N/A
6/30/20212,623466-613189N/A
3/31/20212,778634-335364N/A
12/31/20202,587667116622N/A
9/30/20202,532719187514N/A
6/30/20202,464713258515N/A
3/31/20202,181624203509N/A
12/31/20192,11158674428N/A
9/30/20192,04652979465N/A
6/30/20191,799377-1350N/A
3/31/20191,666271-28230N/A
12/31/20181,467164-10179N/A
9/30/20181,30973-11928N/A
6/30/20181,22665N/A7N/A
3/31/20181,20189N/A87N/A
12/31/20171,188100N/A102N/A
9/30/20171,149128N/A78N/A
3/31/20171,055109N/A108N/A
12/31/20161,082122N/A165N/A
12/31/201584050N/A15N/A
12/31/201477724N/A80N/A
12/31/201372334N/A40N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300702's forecast earnings growth (71.4% per year) is above the savings rate (2.8%).

Earnings vs Market: 300702's earnings (71.4% per year) are forecast to grow faster than the CN market (25.7% per year).

High Growth Earnings: 300702's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300702's revenue (16.8% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 300702's revenue (16.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300702's Return on Equity is forecast to be low in 3 years time (7.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 01:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Tianyu Pharmaceutical Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.
Wei LiuHaitong International Research Limited